

FOR THE RECORD

Cloning, expression, and crystallization of a hyperthermophilic protein that is homologous to the eukaryotic translation initiation factor, eIF5A

KYEONG KYU KIM, HISAO YOKOTA, ROSALIND KIM, and SUNG-HOU KIM

Structural Biology Division of Lawrence Berkeley National Laboratory and Department of Chemistry,
University of California, Berkeley, California 94720

(RECEIVED May 7, 1997; ACCEPTED June 6, 1997)

Abstract: A gene coding for a protein homologous to a translation initiation factor of eukaryotes, eIF5A, was cloned from *Methanococcus jannaschii*, a hyperthermophile with an optimum growth temperature of 85 °C. The protein was overexpressed, purified and crystallized. The crystals were obtained by vapor diffusion method with 8% PEG 4000 as precipitant and belong to space group P4₁22 with unit cell dimensions $a = b = 45.52$ Å and $c = 155.59$ Å. These crystals diffract to at least 2.2 Å resolution.

Keywords: hyperthermophile; *Methanococcus jannaschii*; translation initiation factor; X-ray crystallography

Eukaryotic translation initiation factor 5A, eIF5A, is a universal protein found in all eukaryotic cells (Park et al., 1993a). It is the only protein which is known to have the unusual amino acid residue hypusine [N^ε-(4-amino-2-hydroxybutyl)-L-lysine] (Cooper et al., 1984). The protein was initially isolated in the process of ribosome purification and has been considered as the enzyme involved in the formation of the first peptide bond (Kemper et al., 1976). However, it is known that the complete depletion of eIF5A does not cause major changes in the rate of protein biosynthesis *in vivo* (Kang & Hershey, 1994). Since the necessity for hypusine-modified eIF5A for cell proliferation is well established (Park et al., 1993b) and both protein and its hypusine residue are essential for cell viability (Schnier et al., 1991), the protein's exact role *in vivo* may extend beyond its role in translation initiation. It is also known that the inhibition of hypusine formation correlates with the G1-S transition of the cell cycle (Hanuske-Abel et al., 1994).

Recently, eIF5A was found to be the cofactor of Rev protein of human immunodeficiency virus type 1 (HIV-1) and of Rex protein of human T-cell leukemia virus type I (HTLV-I). Because Rev/Rex activity mediates the translocation of viral mRNAs from the nu-

cleus to the cytoplasm, it seems possible that eIF5A might interact with a nuclear RNA export system (Ruhl et al., 1993; Katahira et al., 1995).

We have cloned the *Methanococcus jannaschii* gene, MJ eIF5A, encoding the homolog of eIF5A by polymerase chain reaction (PCR) amplification. The protein coded by MJ eIF5A has 31% amino acid sequence identity with human eIF5A and 49.6% with that from *Sulfolobus acidocaldarius*, another Archaea. The well-conserved sequences surrounding the lysine modification site strongly suggest a common ancestry between this archaeal protein and eukaryotic eIF5A. In the conserved region of 36 amino acids, one finds 58% identity between *M. jannaschii* and human eIF5A.

We have chosen a hyperthermophile as a source for the protein because the proteins from hyperthermophiles are usually very stable, easy to purify, and often crystallize easily. *M. jannaschii* belongs to Archaea with an optimum growth temperature near 85 °C. To understand the structural basis for the function of eIF5A and for the extreme stability of the MJ eIF5A protein, we have purified and crystallized the eIF5A homolog from *M. jannaschii* for the purpose of crystal structure determination.

Results and discussion: *Cloning:* The MJ eIF5A gene was amplified by PCR using *M. jannaschii* genomic DNA as template and two oligonucleotide primers (A and B). Upstream primer A (5'-A AGG ATC CAT ATG GTG ATA ATA ATG CCA GGA ACA AAA C-3') contains an NdeI (underlined) restriction site at its 5' end. The ATG within the NdeI site is utilized as the translation start site and adds an extra methionine to the N-terminus of MJ eIF5A. Downstream primer B (5'-AA GGA TCC CTC GAG TCA CTT TCC ACC AAT AAC TCT TG-3') contains a BamHI (underlined) restriction site. The blunt-ended 335 bp PCR product was purified using a Qiaquick PCR Purification kit (Qiagen), ligated into the SmaI site of Bluescript SK+ (Stratagene) and transformed into *Escherichia coli* XL-1-Blue [recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F'proAB lacI^qZdM15 Tn10 (Tet^r)] with selection on Xgal plates containing ampicillin (50 µg/mL). White colonies were picked and the MJ eIF5A gene was sequenced to confirm that no mutations were present. The Bluescript clone was

Reprint requests to: Sung-Hou Kim, Structural Biology Division, Lawrence Berkeley National Laboratory, Calvin Lab, 3-220, Berkeley, California 94720; e-mail: SHK@LBL.gov.

then restricted with NdeI and BamHI and the gene was gel isolated and ligated into NdeI/BamHI-restricted pET21a vector (Novagen). The ligation mixture was transformed into BL21 (DE3) pSJS1240 (a gift from Dr. S. Sandler), a strain that carries a plasmid that expresses the rare *E. coli* tRNA codons for arginine (AGA) and isoleucine (ATA). Clones were checked for expression of the MJ eIF5A gene.

Bacterial expression and protein purification: The *E. coli* cells BL21 (DE3) pSJS1240 harboring pET21a/MJ eIF5A plasmid were grown at 37 °C in LB medium containing 50 µg/mL of ampicillin and 30 µg/mL of spectinomycin. At an OD₆₀₀ = 0.9, the MJ eIF5A protein was induced with 0.5 mM of IPTG for 2 h. The cells were harvested by centrifugation (5,000 × *g* for 6 min) and washed with buffer A (25 mM Tris-HCl, pH 7.5, 10% glycerol, 2 mM DTT, 1 mM EDTA). The cell pellet was resuspended in buffer A containing 1 mM PMSF and sonicated for 30 s three times. Broken cells were incubated at 80 °C for 30 min to precipitate heat unstable proteins from *E. coli*. The supernatant was collected after centrifugation for 20 min at 40,000 × *g* in a Beckman Ti60 rotor and applied onto a 5-mL HiTrap SP column (Pharmacia) previously equilibrated with buffer B (25 mM potassium phosphate, pH 7.0, 2 mM EDTA, 2 mM DTT). The column was washed with buffer B until OD₂₈₀ was below 0.05. A 30-mL linear gradient of 0–0.5 M NaCl in buffer B was applied. The MJ eIF5A protein eluted at 0.3 M NaCl. Fractions were pooled and concentrated by ultrafiltration (Amicon, YM3) before loading onto a 1.5 cm × 90 cm S-200 HR gel filtration column (Pharmacia) equilibrated with buffer B containing 100 mM NaCl. The fractions containing the MJ eIF5A protein were pooled and concentrated by ultrafiltration (Amicon, YM3) and dialyzed against distilled water until the protein precipitated in the dialysis bag. Precipitated protein was collected by centrifugation and solubilized in buffer C (25 mM Hepes, pH 7.4, 2 mM EDTA, 2 mM DTT). The protein concentration measured by absorbance at 280 nm was calculated using an extinction coefficient of 0.26.

Selenomethionine substituted MJ eIF5A: The clone containing the structural gene of the MJ eIF5A homolog was transformed into *E. coli* mutant B834 [F⁻ ompT hsdS_B(r_B⁻ m_B⁻) gal dcm met (DE3)], a methionine auxotroph (Novagen). *E. coli* cells were grown at 37 °C in M9 minimal media containing 45 µg/mL selenomethionine, 50 µg/mL of ampicillin, and 30 µg/mL of spectinomycin. Selenomethionine containing MJ eIF5A was purified the same way as the wild-type MJ eIF5A. The difference in molecular weight between the substituted and wild type protein was checked by electrospray mass spectrometry, confirming that all six methionine sites, including the first methionine, were substituted by six selenomethionines.

Crystallization: The purity of the expressed MJ eIF5A protein was determined by SDS gel electrophoresis and electrospray mass spectrometry. Protein was prepared in buffer C at a concentration of 10 mg/mL. Crystallization conditions were tested using the sparse matrix sampling method (Jancarik & Kim, 1991) and membrane protein screen (Hampton Research) using the hanging drop vapor diffusion method with 2 µL drops (1 µL of protein + 1 µL of mother liquor) equilibrated against 500 µL of reservoir solution at 4 °C as well as room temperature. Tetragonal bipyramidal crystals were obtained in sodium acetate buffer (pH 4.6) and polyethylene

Table 1. Data collection statistics (the last resolution bin)

Resolution	30.0–2.6 Å (2.69–2.60 Å)
Total observations	15,214
Tnique reflections	5,371
R_{sym}^a	6.2% (28.3%)
Completeness	96.8% (83.0%)

$$^a R_{sym} = \sum(\langle I \rangle - I) / \sum I.$$

glycol (PEG 350, PEG 4K, PEG 8K) conditions at room temperature. Crystals grew within a week to a size of 0.3 mm × 0.3 mm × 0.6 mm in 0.1 M sodium acetate buffer, pH 4.6, 8% PEG 4K.

Selenomethionine substituted protein did not crystallize in the same condition as wild-type protein. Initial crystallization conditions were searched using the sparse matrix sampling method at room temperature. Crystallization conditions were optimized by addition of 5 mM L-methionine and 5 mM CaCl₂ in the drops. Crystals in the shape of long needles grew within a week to a size of 0.15 mm × 0.15 mm × 1.0 mm in 0.1 M Tris-HCl, pH 8.5, and 8% PEG 8K.

Space group determination: Preliminary X-ray data were collected on a Rigaku R-Axis IIC imaging plate system, using Cu K α radiation from a Rigaku RU200 B rotating anode operated at 40 kV and 100 mA with a MSC focusing mirror. Fully grown crystals were mounted in a glass capillary and data were collected at room temperature. Possible space group and unit cell parameters were predicted by DENZO data processing software (Otwinowski, 1993). The space group was determined to be P4₁22 and the refined cell parameters are $a = b = 45.52$ Å and $c = 155.59$ Å. Assuming the molecular weight of 14,636 Da and one molecule in the asymmetric unit, a solvent content of 55% and a volume to mass ratio $V_m = 2.76$ Å³/Da (Matthews, 1968) were calculated. Data were processed and integrated by DENZO and scaled by SCALEPACK (Otwinowski, 1993). Crystals diffracted to 2.2 Å at the beginning of the data collection but decayed quickly. Complete native data sets were collected to 2.6 Å with R_{sym} of 6.2% and data statistics are summarized in Table 1. The crystals from the selenomethionine substituted protein diffracted to 3.0 Å when crystals were frozen at 100 K and were indexed in a triclinic space group with cell dimensions of $a = 45.99$ Å, $b = 48.33$ Å, $c = 64.74$ Å, $\alpha = 103.0^\circ$, $\beta = 99.9^\circ$, and $\gamma = 111.6^\circ$.

Acknowledgments: We are very grateful to Dimitry Lerner and Steve Santoso for technical assistance. We also thank Dr. Stan Goldman for providing us with *M. jannaschii* genomic DNA, Dr. Doug Clark for *M. jannaschii* cells, Dr. S. Sandler for the plasmid pSJS1240, and Dr. David King for performing the electrospray mass spectrometry. This work was supported by the Director, Office of Energy Research, Office of Health Effects and Environment Research, U.S. Department of Energy under Contract No. DE-AC03-76SF00098 (R.K. and S.H.K.).

References

- Cooper HL, Park MH, Folk JE. 1984. Hypusine formation: A unique posttranslational modification in translation initiation factor eIF-4D. *Methods in Enzymology* 106:344–351.
- Hanuske-Abel HM, Park H, Hanuske AR, Popowicz AM, Lalande M, Folk JE. 1994. Inhibition of the G1-S transition of the cell cycle by inhibitors of deoxyhypusine hydroxylation. *Biochim Biophys Acta* 1221:115–124.

- Jancarik J, Kim SH. 1991. Sparse matrix sampling: A screening method for crystallization of proteins. *J Appl Crystallogr* 24:409–411.
- Kang HA, Hershey JWB. 1994. Effect of initiation factor eIF-5A depletion on protein synthesis and proliferation of *Saccharomyces cerevisiae*. *J Biol Chem* 269:3934–3940.
- Katahira J, Ishizaki T, Sakai H, Adachi A, Yamamoto K, Shida H. 1995. Effects of translation initiation factor eIF-5A on the functioning of human T-cell leukemia virus type I Rex and human immunodeficiency virus Rev inhibited trans dominantly by a Rex mutant deficient in RNA binding. *J of Virology* 69:3125–3133.
- Kemper WM, Berry KW, Merrick WC. 1976. Purification and properties of rabbit reticulocyte protein synthesis initiation factors M2B α and M2B β . *J Biol Chem* 251:5551–5557.
- Matthews BW. 1968. Solvent content of protein crystals. *J Mol Biol* 33:491–497.
- Otwinowski Z. 1993. Oscillation data reduction program. In: Sawyer L, Isaacs N, and Bailey S, eds. *Data collection and processing*. Warrington, United Kingdom: SERC Daresbury Laboratory. pp 56–62.
- Park MH, Wolff EC, Folk JE. 1993a. Hypusine: Its post-translational formation in eukaryotic initiation factor 5A and its potential role in cellular regulation. *Biofactors* 4:95–104.
- Park MH, Wolff EC., Folk JE. 1993b. Is hypusine essential for eukaryotic cell proliferation? *Trends Biochem Sci* 18:475–479.
- Ruhl M, Himmelspach M, Bahr GM, Hammerschmid F, Jaksche H, Wolff B, Aschauer H, Farrington GK, Probst H, Bevec D. 1993. Eukaryotic initiation factor 5A is a cellular target of the human immunodeficiency virus type I Rev activation domain mediating trans-activation. *J Cell Biol* 123:1309–1320.
- Schnier J, Schwelberger HG, Smitmcbride Z, Kang HA, Hershey JWB. 1991. Translation initiation factor 5A and its hypusine modification are essential for cell viability in the yeast *Saccharomyces cerevisiae*. *Mol Cell Biol* 11:3105–3114.